Immunovant, Inc. (IMVT)
NASDAQ: IMVT · Real-Time Price · USD
34.15
+0.02 (0.06%)
At close: May 22, 2026, 4:00 PM EDT
34.15
0.00 (-0.01%)
After-hours: May 22, 2026, 7:57 PM EDT
Immunovant Market Cap
Immunovant has a market cap or net worth of $7.01 billion as of May 22, 2026. Its market cap has increased by 188.65% in one year.
Market Cap
7.01B
Enterprise Value
6.11B
1-Year Change
188.65%
Ranking
Category
Stock Price
$34.15
Market Cap Chart
Since June 21, 2019, Immunovant's market cap has increased from $124.38M to $7.01B, an increase of 5,537.23%. That is a compound annual growth rate of 79.03%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| May 22, 2026 | 7.01B | 36.09% |
| Dec 31, 2025 | 5.15B | 41.70% |
| Dec 31, 2024 | 3.64B | -40.34% |
| Dec 29, 2023 | 6.09B | 165.79% |
| Dec 30, 2022 | 2.29B | 134.03% |
| Dec 31, 2021 | 979.80M | -78.33% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Jun 21, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Nuvalent | 8.12B |
| Halozyme Therapeutics | 8.10B |
| ImmunityBio | 7.69B |
| Bio-Techne | 7.42B |
| Vaxcyte | 6.88B |
| Celcuity | 6.79B |
| Kymera Therapeutics | 6.53B |
| Protagonist Therapeutics | 6.47B |